

MDNA Life Sciences (UK) Limited**Registered number:** 05386828**Balance Sheet****as at 30 September 2016**

	Notes	2016 £	2015 £
Fixed assets			
Tangible assets	2	43,426	54,282
Current assets			
Debtors	3	54,531	26,587
Cash at bank and in hand		15,831	6,662
		<u>70,362</u>	<u>33,249</u>
Creditors: amounts falling due within one year	4	(293,345)	(173,807)
Net current liabilities		<u>(222,983)</u>	<u>(140,558)</u>
Net liabilities		<u>(179,557)</u>	<u>(86,276)</u>
Capital and reserves			
Called up share capital		1	1
Profit and loss account		(179,558)	(86,277)
Shareholders' funds		<u>(179,557)</u>	<u>(86,276)</u>

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

H E Smart

Director

Approved by the board on 3 January 2017

MDNA Life Sciences (UK) Limited
Notes to the Accounts
for the year ended 30 September 2016

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Tangible fixed assets

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Plant and machinery	20% on reducing balance basis
---------------------	-------------------------------

Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

Taxation

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Leased assets

Operating lease payments are recognised as an expense on a straight line basis over the lease term.

2 Tangible fixed assets

	Plant and machinery etc £
Cost	
At 1 October 2015	125,833
At 30 September 2016	<u>125,833</u>
Depreciation	
At 1 October 2015	71,551
Charge for the year	10,856
At 30 September 2016	<u>82,407</u>
Net book value	
At 30 September 2016	<u>43,426</u>
At 30 September 2015	<u>54,282</u>

3 Debtors	2016	2015
	£	£
Other debtors	<u>54,531</u>	<u>26,587</u>

4 Creditors: amounts falling due within one year	2016	2015
	£	£

Amounts owed to group undertakings and undertakings in which the company has a participating interest

288,398	47,057
---------	--------

Other taxes and social security costs	2,921	4,474
Other creditors	2,026	122,276
	<u>293,345</u>	<u>173,807</u>

5 Controlling party

The company is wholly owned subsidiary of MDNA Life Sciences Inc, a company incorporated in the USA.

6 Other information

MDNA Life Sciences (UK) Limited is a private company limited by shares and incorporated in England. Its registered office is:

A1 Marquis Court
Team Valley
Gateshead
Tyne and Wear
NE11 0RU

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.